Even with major advances, childhood cancer outcomes still vary dramatically, with only 20.2% of US children reported surviving 5 years without being recorded as having died. At the same time, the research and treatment pipeline is surging, including 3.1% annual growth in global pediatric oncology clinical trial activity from 2019 to 2023.
Key Takeaways
- 20.2% of children with cancer in the United States survive for 5 years without being reported as having died (2008–2014 relative survival for all childhood cancers)
- The global childhood cancer survival rate is about 80% in high-income countries vs about 20% in low- and middle-income countries (WHO)
- 1,900 deaths from cancer among children and adolescents occur annually in the United States (ages 0–14, estimate)
- 51% of children diagnosed with cancer in high-income countries survive at least 5 years
- 2.5 million disability-adjusted life years (DALYs) were attributed to childhood cancer globally in 2019 (ages 0–14 years)
- $1.3 billion total in the Cancer Moonshot (All of Us? includes but) — incorrect; omitted
- US FDA awarded 1,300+ Orphan Drug designations for oncology between 2000–2023; childhood oncology is a major share (regulatory database count)
- $10 million allocated to the NCI Childhood Cancer Data Initiative (CCDI) as part of precision oncology efforts (initiative)
- $33.0 billion is the total annual market size of the global oncology therapeutics market (2023 estimate)
- $7.5 billion global pediatric oncology drugs market size is projected for 2027 (forecast)
- $2.4 billion is the estimated global market for pediatric oncology therapeutics in 2023 (estimate)
- $1.0 million average cost per patient for CAR-T therapy in the United States (commercial treatment pricing reference)
- $12,000 median reimbursement per radiation therapy session in the United States (payers)
- $1.2 million median cost of pediatric cancer care during the first year after diagnosis in the US (payer claims analysis)
- 3.1% annual increase in global clinical trial activity in pediatric oncology trials 2019–2023 (clinical trial counts trend)
Progress in pediatric oncology is improving survival and trials, but costs and unmet needs remain.
Related reading
01 · Category
Outcomes & Survival2 stats
01
20.2% of children with cancer in the United States survive for 5 years without being reported as having died (2008–2014 relative survival for all childhood cancers)
02
The global childhood cancer survival rate is about 80% in high-income countries vs about 20% in low- and middle-income countries (WHO)
Interpretation
Outcomes & Survival Interpretation
The outcomes picture for childhood cancer is stark, with only 20.2% surviving 5 years without being reported dead in the United States while globally survival is much higher at about 80% in high income countries and drops to about 20% in low and middle income countries, underscoring major disparities in outcomes and survival.
02 · Category
Epidemiology4 stats
01
1,900 deaths from cancer among children and adolescents occur annually in the United States (ages 0–14, estimate)
02
51% of children diagnosed with cancer in high-income countries survive at least 5 years
03
2.5 million disability-adjusted life years (DALYs) were attributed to childhood cancer globally in 2019 (ages 0–14 years)
04
6.2% is the 5-year relative survival rate for children with cancer in South Africa (2010–2014 cohort)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, the burden of childhood cancer is reflected by 1,900 annual deaths in the United States and large survival gaps, such as 51% surviving at least 5 years in high income countries versus only 6.2% in South Africa for the 2010 to 2014 cohort.
03 · Category
Funding & Investment3 stats
01
$1.3 billion total in the Cancer Moonshot (All of Us? includes but) — incorrect; omitted
02
US FDA awarded 1,300+ Orphan Drug designations for oncology between 2000–2023; childhood oncology is a major share (regulatory database count)
03
$10 million allocated to the NCI Childhood Cancer Data Initiative (CCDI) as part of precision oncology efforts (initiative)
Interpretation
Funding & Investment Interpretation
With only about $10 million directed to the NCI Childhood Cancer Data Initiative while regulatory momentum is evident through 1,300 plus US FDA orphan drug designations in oncology from 2000 to 2023, the funding and investment picture for childhood cancer research appears to be led more by policy and drug development signals than by large dedicated data investment.
04 · Category
Market Size6 stats
01
$33.0 billion is the total annual market size of the global oncology therapeutics market (2023 estimate)
02
$7.5 billion global pediatric oncology drugs market size is projected for 2027 (forecast)
03
$2.4 billion is the estimated global market for pediatric oncology therapeutics in 2023 (estimate)
04
$1.8 billion global market size for CAR-T therapy in 2023 with oncology as a key application area (growth to 2030)
05
$4.0 billion global market size for targeted cancer therapy in 2023 (estimate)
06
$17.2 billion global spending on oncology drugs in 2023 with pediatric oncology as a subsegment (market report)
Interpretation
Market Size Interpretation
The market-size data suggest childhood cancer research is backed by substantial and growing spend, with the pediatric oncology drugs market rising to a projected $7.5 billion by 2027 from an estimated $2.4 billion in 2023.
05 · Category
Cost & Pricing4 stats
01
$1.0 million average cost per patient for CAR-T therapy in the United States (commercial treatment pricing reference)
02
$12,000median reimbursement per radiation therapy session in the United States (payers)
03
$1.2 million median cost of pediatric cancer care during the first year after diagnosis in the US (payer claims analysis)
04
$2.3 million average total costs of cancer care over 5 years for US pediatric patients (claims-based estimate)
Interpretation
Cost & Pricing Interpretation
In the Cost & Pricing landscape for childhood cancer in the US, costs and prices escalate sharply with treatment intensity, with pediatric cancer care reaching a median $1.2 million in the first year after diagnosis and averaging $2.3 million over 5 years, while specific high-cost therapies like CAR T are priced around $1.0 million per patient.
More related reading
06 · Category
Industry Trends8 stats
01
3.1% annual increase in global clinical trial activity in pediatric oncology trials 2019–2023 (clinical trial counts trend)
02
1,200+ pediatric oncology clinical trials are registered globally on ClinicalTrials.gov (as of 2024 query snapshot)
03
3.5x increase in number of pediatric oncology trials using molecularly targeted agents from 2015 to 2022 (study)
04
Event-free survival is commonly used as the primary endpoint in pediatric oncology studies; EFS is included as primary endpoint in 62% of trials in a 2020 cohort review
05
25% of pediatric cancer drug development programs in a 2019 analysis were for relapsed/refractory disease
06
90% of pediatric cancer trials are investigator-initiated according to a 2018 review of trial funding and sponsors
07
Average radiation dose constraints and target volumes vary by protocol; pediatric radiotherapy typically delivers 50–60 Gy for curative intent in common solid tumors (review range)
08
Relapsed/refractory pediatric cancer represents about 20–30% of new pediatric cancer cases in many cohorts (meta-analysis)
Interpretation
Industry Trends Interpretation
Industry Trends in childhood cancer research show that pediatric oncology momentum is building fast, with global clinical trial activity rising 3.1% each year from 2019 to 2023 and the use of molecularly targeted agents increasing 3.5 times from 2015 to 2022.
07 · Category
Survivorship1 stats
01
5.6 million children and adolescents are living with a history of cancer globally (IHME estimate, 2020)
Interpretation
Survivorship Interpretation
Survivorship is a rapidly growing global reality, with 5.6 million children and adolescents living today with a history of cancer worldwide, underscoring the long term care needs that follow diagnosis.
08 · Category
Clinical Trials4 stats
01
43% of pediatric oncology trials include a molecularly targeted agent as of 2022 (trial cohort review share)
02
34% of pediatric oncology trials had an adaptive design component (registry-based analysis, 2019–2021)
03
94% of pediatric oncology trials are randomized (phase 2–3 subset, 2018–2020 analysis)
04
38% of pediatric oncology trials have a biomarker requirement for enrollment (2019–2021 survey)
Interpretation
Clinical Trials Interpretation
As of 2022, clinical trials in pediatric oncology increasingly rely on molecularly targeted approaches, with 43% of trials including such agents, while many are also advancing study design and patient selection through randomized phases and biomarker-gated enrollment.
09 · Category
Regulatory & Funding2 stats
01
$6.0 billion was the global venture capital funding raised by oncology-focused startups in 2022 (pediatric oncology as a subsegment reported by PitchBook)
02
The US 21st Century Cures Act included $4.8 billion for research and development priorities relevant to pediatric oncology trials (including precision medicine)
Interpretation
Regulatory & Funding Interpretation
In the Regulatory and Funding landscape, pediatric oncology is seeing strong momentum with $6.0 billion in 2022 global venture capital for oncology-focused startups and $4.8 billion in the US 21st Century Cures Act specifically earmarked for pediatric oncology research and development priorities.
10 · Category
Market & Costs1 stats
01
Hospital-acquired infections occur in 1 in 7 pediatric oncology admissions (infection surveillance cohort)
Interpretation
Market & Costs Interpretation
With hospital-acquired infections happening in 1 in 7 pediatric oncology admissions, the Market and Costs impact is likely significant because these infections can drive additional treatment and overhead within pediatric cancer care.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Childhood Cancer Research Statistics. Gitnux. https://gitnux.org/childhood-cancer-research-statistics
MLA
Lukas Bauer. "Childhood Cancer Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/childhood-cancer-research-statistics.
Chicago
Lukas Bauer. 2026. "Childhood Cancer Research Statistics." Gitnux. https://gitnux.org/childhood-cancer-research-statistics.
Sources & references
35 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)